Table 1.

Role of m6A regulator in chemotherapy

Drug	Regulator	Role	Level	Cancer		Target	Effect	References
Cisplatin	METTL3	Oncogene	High	NSCLC		AKT1	enhances expression of AKT1	[35]
Cisplatin	METTL3	Oncogene	NA	NSCLC		miR-486	promotes the maturation of pri-miR-486	[36]
Cisplatin	METTL3	Suppressor	Low	NSCLC		FSP1	enhances expression of FSP1	[37]
Cisplatin	YTHDF1	Suppressor	Low	NSCLC		KEAP1	Promotes transcription of KEAP1	[38]
Cisplatin	METTL3	Oncogene	NA	GC		ARHGAP5	Facilitates translation of ARHGAP5	[39]
Oxaliplatin	METTL3	Oncogene	High	GC		PARP1	stabilizes PARP1 mRNA via YTHDF1	[12]
Cisplatin	YTHDF2	Oncogene	NA	GC		CBS	Promotes degradation of CBS mRNA	[40]
Cisplatin	METTL14	Oncogene	NA	GC		c-Myc	stabilizes c-Myc mRNA via a potential reader, MSI2	[41, 42]
Oxaliplatin	METTL3	Oncogene	High	CRC		CBX8	stabilizes CBX8 mRNA via IGF2BP1	[43]
Oxaliplatin	METTL3	Oncogene	High	CRC		TRAF	Promotes TRAF mRNA degradation	[44]
Cisplatin	YTHDF1	Oncogene	High	CRC		GLS1	promoted translation of GLS1	[45]
Oxaliplatin	YTHDF3	Oncogene	High	CRC		ATP7A, DYRK1B	promotes translation of ATP7A and DYRK1B	[46]
Cisplatin	ALKBH5	Oncogene	High	EOC		JAK2	Promotes expression of JAK2	[47]
Cisplatin	YTHDF1	Oncogene	NA	OC		TRIM29	Promotes translation of TRIM29	[48]
Cisplatin	METTL3	Oncogene	High	Seminoma		TFAP2C	increased expression of TFAP2C via IGF2BP1	[49]
Cisplatin	METTL3	Oncogene	High	Seminoma		ATG5	Enhances expression of ATG5	[13]
Cisplatin	ALKBH5	Oncogene	High	OSCC		FOXM1, NANOG	Promotes expression of FOXM1 and NANOG	[50]
Cisplatin	FTO	Oncogene	High	OSCC		/	/	[51]
Cisplatin	METTL3	Oncogene	High	NPC		TRIM11	Stabilizes TRIM11 via IGF2BP2	[14]
Cisplatin	WTAP	Oncogene	High	NKTCL		TNFAIP3	Stabilizing TNFAIP3 mRNA	[52]
Cisplatin	WTAP	Oncogene	High	NKTCL		DUSP6	Increases stability of DUSP6 mRNA	[53]
Cisplatin	VIRMA	Oncogene	High	GCT		XLF, MRE11	Enhances expression of XLF and MRE11	[54]
Temozolomide	METTL3	Oncogene	High	GBM		MGMT and ANPG	Increases expression of MGMT and ANPG	[55]
Temozolomide	FTO	Oncogene	NA	GBM		PDK1	Reduces degradation of PDK1 mRNA	[56]
Temozolomide	ALKBH5	Oncogene	High	GBM		NANOG	Reduces degradation of NANOG mRNA	[57]
Gemcitabine	METTL3	Suppressor	Low	PC		lncRNA DBH-AS1	Promotes DBH-AS1 RNA stability	[58]
Gemcitabine	METTL14	Oncogene	High	PC		CDA	Stabilizes CDA mRNA	[59]
Gemcitabine	ALKBH5	Suppressor	Low	PDAC		WIF-1	Promotes transcription of WIF-1	[60]
Gemcitabine	SRSF3	Oncogene	High	PC		lncRNA ANRIL	Regulates alternative splicing ANRIL to increase the ANRIL-L isoform	[61]
5-Fluorouracil	METTL3	Oncogene	High	CRC	miR181b5p		Promotes the miR181b5p process by DGCR8	[62]
5-Fluorouracil	METTL3	Oncogene	High	CRC	LBX2-AS1		Stabilizes LBX2-AS1 via IGF2BP1	[63]
5-Fluorouracil	METTL3	Oncogene	High	CRC	SEC62		Promotes expression of SEC62	[64]
5-Fluorouracil	METTL3	Oncogene	High	CRC	P53		Promotes preferential splicing of p53 pre-mRNA, inducing p53 R273H mutant protein	[65]
Doxorubicin	METTL3	Oncogene	High	BC	MALAT1		METTL3 promotes MALAT1 expression level	[66]
Doxorubicin	METTL3	Oncogene	High	BC	miR-221-3p		Promotes process of miR-221-3p	[67]
Doxorubicin	METTL3	Oncogene	High	BC	ERRγ		Promotes expression of ERRγ	[68]
Doxorubicin	WTAP	Oncogene	High	BC	DLGAP1-AS1		Increases the stability of DLGAP1-AS1	[69]
Doxorubicin Cisplatin, Olaparib	YTHDF1	Oncogene	NA	BC	E2F8		YTHDF1 enhances the E2F8 mRNA stability	[70]
Doxorubicin	FTO	Oncogene	High	BC	STAT3		Promotes expression of STAT3	[71]
Doxorubicin	IGF2BP3	Oncogene	High	CRC	ABCB1		ABCB1 increases the stability of ABCB1 mRNA	[72]
Doxorubicin, Methotrexate	METTL3	Suppressor	Low	OS	TRIM7		Promotes degradation of TRIM7 via YTHDF2	[73]
Doxorubicin	METTL3	Oncogene	High	CML	PTEN		Promotes degradation of TRIM7 via PTEN	[74]
Bortezomib, Melphalan, Carfilzomib	METTL7A	Oncogene	NA	MM	LOC606724 and SNHG1		promotes enrichment of lncRNAs into exsomes	[75]
Arabinocytosine	METTL3	Oncogene	High	AML	MYC		Increases expression of MYC	[76]
Penicillin, Streptomycin	METTL3	Suppressor	Low	AML	AKT		Decreases expression of AKT	[77]
Dexamethasone	ALKBH5	Oncogene	NA	T-ALL	USP1		Increasing stability of USP1 mRNA	[78]